<?xml version="1.0" encoding="UTF-8"?>
<p>It is essential to determine similarity between the bio-similar and the reference product. Tests should be done with regard to physicochemical characteristics (structure), biological activity/potency (function), safety, and efficacy profiles.
 <xref rid="b9-dddt-12-2381" ref-type="bibr">9</xref>,
 <xref rid="b10-dddt-12-2381" ref-type="bibr">10</xref> In the process of biosimilar development, clinical pharmacology plays a critical part as it provides evidence that there are no clinically meaningful differences in terms of pharmacokinetics (PKs) and pharmacodynamics (PDs).
 <xref rid="b11-dddt-12-2381" ref-type="bibr">11</xref> To prove biosimilarity between the test filgrastim product and its reference filgrastim product, we conducted a comparative clinical trial of the 2 products.
</p>
